Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896887033> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2896887033 endingPage "S1027" @default.
- W2896887033 startingPage "S1027" @default.
- W2896887033 abstract "Intensity modulated proton therapy (IMPT) has the potential to reduce dose to adjacent normal tissue compared to photon therapy. Although dosimetric advantages can be seen, these results need to translate to clinically meaningful benefit. We aim to identify patients who would benefit from IMPT over photon volumetric modulated arc therapy (VMAT) in locally advanced lung cancer using recently published normal tissue complications probabilities (NTCP) models for heart and lung. VMAT and robust optimised-IMPT plans were assessed to a physical dose of 70Gy in 35 fractions according to RTOG 1308 protocol. Risk estimates of grade 3+ cardiac toxicities and dyspnoea were calculated based on NTCP models which incorporated dose metrics and individual patients’ baseline risk-factors (RF) (cardiac: pre-existing heart disease (HD), lung: patient-reported outcome dyspnoea grade). Risk estimates were calculated and compared based on the pre-treatment patients’ RF and in the hypothetical scenarios where all patients had baseline HD or grade 1 dyspnoea. The difference between the probability estimates of VMAT and IMPT were determined (ΔNTCP). The models were applied in the different scenarios to ten proxy patients. These patients were retrospectively identified to ensure different anatomical locations (lobes and mediastinal/hilar regions) were represented (GTV median: 106cc, range: 15–404cc). Five patients had planning target volume (PTV) overlapping with the heart. There was no significant difference in target coverage between VMAT and IMPT. Protons delivered a lower dose and to heart and lung in all patients (p<0.05, lung: V20, V5, mean lung dose; heart: V30, V5 and mean heart dose). When the risk estimates were calculated according to the patients’ baseline RF, only three had an estimated ΔNTCP≥5%- all based on cardiac toxicities (AR VMAT vs IMPT: 38% vs 10%, 13% vs 10%, 18% vs 9%). Of the three, two patients had pre-existing HD. The relative risk reduction with IMPT varied between none to 0.74. Using ΔNTCP≥5% as a threshold, when all patients were considered to either have baseline HD or grade 1 dyspnoea, the same three patients were selected based on cardiac toxicities and two based on lung toxicity. Predictors of ΔNTCP≥5% for cardiac toxicities were pre-existing cardiac disease, tumour volume extending to the level of T7 vertebrae or below, degree of overlap between PTV and heart. In an unselected patient group, not all patients would benefit from IMPT. Although the validity of photon NTCP models in proton is unclear, appropriate models could be used to aid randomised control trial design." @default.
- W2896887033 created "2018-10-26" @default.
- W2896887033 creator A5008310263 @default.
- W2896887033 creator A5018289554 @default.
- W2896887033 creator A5074404084 @default.
- W2896887033 creator A5083509294 @default.
- W2896887033 creator A5091101451 @default.
- W2896887033 date "2018-10-01" @default.
- W2896887033 modified "2023-09-30" @default.
- W2896887033 title "P3.17-18 Towards Individualizing Patient Selection in Proton Therapy for Lung Cancer Using the Model-Based Approach" @default.
- W2896887033 doi "https://doi.org/10.1016/j.jtho.2018.08.1974" @default.
- W2896887033 hasPublicationYear "2018" @default.
- W2896887033 type Work @default.
- W2896887033 sameAs 2896887033 @default.
- W2896887033 citedByCount "0" @default.
- W2896887033 crossrefType "journal-article" @default.
- W2896887033 hasAuthorship W2896887033A5008310263 @default.
- W2896887033 hasAuthorship W2896887033A5018289554 @default.
- W2896887033 hasAuthorship W2896887033A5074404084 @default.
- W2896887033 hasAuthorship W2896887033A5083509294 @default.
- W2896887033 hasAuthorship W2896887033A5091101451 @default.
- W2896887033 hasBestOaLocation W28968870331 @default.
- W2896887033 hasConcept C126322002 @default.
- W2896887033 hasConcept C126838900 @default.
- W2896887033 hasConcept C2776256026 @default.
- W2896887033 hasConcept C2777714996 @default.
- W2896887033 hasConcept C2779244869 @default.
- W2896887033 hasConcept C2989005 @default.
- W2896887033 hasConcept C509974204 @default.
- W2896887033 hasConcept C71924100 @default.
- W2896887033 hasConceptScore W2896887033C126322002 @default.
- W2896887033 hasConceptScore W2896887033C126838900 @default.
- W2896887033 hasConceptScore W2896887033C2776256026 @default.
- W2896887033 hasConceptScore W2896887033C2777714996 @default.
- W2896887033 hasConceptScore W2896887033C2779244869 @default.
- W2896887033 hasConceptScore W2896887033C2989005 @default.
- W2896887033 hasConceptScore W2896887033C509974204 @default.
- W2896887033 hasConceptScore W2896887033C71924100 @default.
- W2896887033 hasIssue "10" @default.
- W2896887033 hasLocation W28968870331 @default.
- W2896887033 hasOpenAccess W2896887033 @default.
- W2896887033 hasPrimaryLocation W28968870331 @default.
- W2896887033 hasRelatedWork W1482155229 @default.
- W2896887033 hasRelatedWork W2068852676 @default.
- W2896887033 hasRelatedWork W2352157767 @default.
- W2896887033 hasRelatedWork W2366314651 @default.
- W2896887033 hasRelatedWork W2378162781 @default.
- W2896887033 hasRelatedWork W2394006323 @default.
- W2896887033 hasRelatedWork W2591994030 @default.
- W2896887033 hasRelatedWork W2800814030 @default.
- W2896887033 hasRelatedWork W2978475839 @default.
- W2896887033 hasRelatedWork W2997440134 @default.
- W2896887033 hasVolume "13" @default.
- W2896887033 isParatext "false" @default.
- W2896887033 isRetracted "false" @default.
- W2896887033 magId "2896887033" @default.
- W2896887033 workType "article" @default.